More studies are needed to validate these findings in large mammalian animal models and to develop NFATC1 nuclear translocation-targeted therapeutic strategies for TNNI3K gene mutation-based cardiomyopathy and CCD. This evidence concerns the gene NFATC1 and cardiomyopathy.